Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram Combination in MDD
NCT00239954Phase 3Unknown
- Sponsor
- Pharmacology Research Institute
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of escitalopram in major depressive disorder (MDD) (4 arms), sponsored by Pharmacology Research Institute. Primary endpoint: Montgomery Asberg Depression Rating Scale at 8 weeks. Status: unknown.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00239954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239954.